Research funded by the National Institutes of Health (NIH) suggests that exposure to specific combinations of allergens and bacteria within the first year of life may protect children from wheezing and allergic disease. These observations come from the Urban Environment and Childhood Asthma (URECA) study, which aims to identify factors responsible for asthma development in children from inner-city settings, where the disease is more prevalent and severe. Since 2005, the URECA study has enrolled 560 children from four cities--Baltimore, Boston, New York and St. Louis. The children all have at least one parent with asthma or allergies, placing them at high risk for developing asthma. The study is following the children from birth, and the current publication evaluates the group through three years of age.
During early life, recurrent wheezing and sensitivity to common allergens are risk factors for developing asthma. In the current study, the researchers measured the frequency of wheezing episodes and levels of exposure to five common inner-city allergens--cat, cockroach, dog, dust mite and mouse. Surprisingly, they found that exposure to cockroach, mouse and cat during the first year of life was associated with a lower risk of recurrent wheezing by age three.
A smaller study within the URECA cohort tested whether bacteria, measured in house dust, influence asthma risk. Researchers sorted 104 children into four groups: no wheezing or sensitivity to allergens, wheezing only, sensitivity to allergens only, or both wheezing and sensitivity to allergens. They found that children with no wheezing or sensitivity to allergens at age three were more likely to have encountered high levels of allergens and a greater variety of bacteria, particularly those belonging to the Bacteriodes and Firmicutes groups, during their first year of life. These observations support the emerging concept that early-life exposure to high bacterial diversity may protect kids from developing allergies. Most importantly, the findings show that this protection is even stronger when children also encounter high allergen levels during this time.
The URECA study, funded by NIH's National Institute of Allergy and Infectious Diseases through its Inner-City Asthma Consortium, is no longer recruiting, but more information is available at ClinicalTrials.gov using the identifier NCT00114881. Additional funding was provided by the NIH's National Center for Advancing Translational Sciences. The research was conducted by investigators from several institutions, including the University of Wisconsin-Madison; the University of California, San Francisco; and Johns Hopkins University.
SV Lynch et al. Effects of early life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2014.04.018 (2014).
NIAID Director Anthony S. Fauci, M.D., and Peter J. Gergen, M.D., Medical Officer in the Asthma and Airway Biology Section in NIAID's Division of Allergy, Immunology and Transplantation, are available to discuss the findings.
To schedule interviews, contact Linda Huynh, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health ®